What Geninus does

Geninus Inc. is a Seoul-headquartered precision genomics company that has built IntelliMed™, a spatial ecosystem intelligence platform designed to enable novel therapeutic target discovery in oncology. The platform integrates multimodal patient data — spatial transcriptomics, multiplexed spatial protein profiling, single-cell data, H&E pathology, and clinically annotated patient datasets — into a unified analytical framework, with the proprietary Spatial Signature Score (SSS) serving as its core scoring engine. SSS ranks targets by clinical relevance using spatial distribution, regional enrichment, and tumor microenvironment context rather than simple abundance, while a Paired Spatial Signature Scoring extension quantifies pair-level spatial context to identify optimal target combinations for clinical development in proven modalities such as T-cell engagers (TCEs) and antibody-drug conjugates (ADCs).

The business model is a B2B enterprise platform sold to pharmaceutical and biotechnology companies through direct sales. Revenue mechanics are described as subscription/recurring platform access, although the website currently lists IntelliMed™ as "Under Construction" and pricing is not publicly disclosed. The underlying proprietary multimodal patient dataset — 5,500+ patient samples, 400+ treatment response-linked spatial datasets, and 1,500+ Xenium spatial datasets — is grown through mutual partnerships with leading global academic medical centers and represents the primary feedstock that differentiates the platform from any public resource. Distribution is handled through direct enterprise engagement with global pharma buyers rather than through channel partners.

Geninus is listed on KOSDAQ under ticker 389030, employs 51–100 people, and is led by CEO Woong Yang Park. The company has raised approximately $34M across multiple funding rounds since 2018, with the most recent 2025-06 ($7.4M) and 2026-03 ($13.6M) rounds led by Korean institutional investors including Company K Partners, KB Investment, Korea Investment Partners, IMM Investment, KTB Network, Aju IB Investment, and VSV Capital. Disclosed financials show annual revenues in the low single-digit million USD range and recurring operating losses in the $5–9M USD range, consistent with a pre-commercial platform investing aggressively in dataset acquisition and analytical capability ahead of full commercial launch.

Name

Geninus

Legal name

Geninus Inc.

Website

https://kr-geninus.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Geninus Inc. is a Seoul-based precision genomics company developing IntelliMed™, a proprietary spatial ecosystem intelligence platform that uses multimodal patient data and proprietary scoring algorithms to enable novel therapeutic target and target-pair discovery in oncology for pharmaceutical and biotechnology clients.

Ownership category

akta.pro rank

Product category

Precision Genomics Analytics Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Spatial transcriptomics platform
• Oncology target discovery
• Precision genomics analytics
• Multimodal patient data
• Therapeutic target identification

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IntelliMed™ Platform Access: Platform-based revenue model providing pharmaceutical companies access to proprietary spatial ecosystem intelligence for novel target discovery in proven modalities including TCEs and ADCs. The platform generates actionable therapeutic targets and identifies optimal target pairs for clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Geninus provides IntelliMed™, a spatial ecosystem intelligence platform that converts proprietary multimodal patient data (spatial transcriptomics, multiplexed spatial protein profiling, single-cell, H&E pathology, and clinically annotated datasets) into actionable therapeutic targets and optimal target pairs for oncology drug discovery. The platform is offered to pharmaceutical and biotech companies for novel target identification in proven modalities such as TCEs and ADCs, powered by a proprietary scoring engine called the Spatial Signature Score (SSS).

Product overview

Geninus offers a single unified product platform called IntelliMed™ — a spatial ecosystem intelligence platform designed for novel target discovery in oncology. The platform is powered by proprietary multimodal patient data and uses the Spatial Signature Score (SSS) as its core analytical engine to rank targets by clinical relevance. An extension called Paired Spatial Signature Scoring extends this capability into combination strategies to identify optimal therapeutic target pairs. These components work together to convert proprietary patient data into actionable therapeutic targets and identify the right target pairs for clinical translation.

Differentiator

Problem solved

Functional benefit

Brands

• IntelliMed™: A proprietary platform for precision genomics that discovers novel therapeutic targets and target pairs using multimodal spatial ecosystem biology. Powered by proprietary patient datasets including spatial transcriptomics, multiplexed spatial protein profiling, and clinical-response spatial data.

Products and services

• IntelliMed™ Spatial ecosystem intelligence platform that converts proprietary multimodal patient data (spatial transcriptomics, multiplexed spatial protein profiling, single-cell, H&E pathology, and clinically annotated patient datasets) into actionable therapeutic targets and optimal target pairs for oncology drug discovery. Designed for pharmaceutical and biotech companies seeking novel target identification in proven modalities such as TCEs and ADCs without biological uncertainty.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

One partnership is on record.

• Leading Global Academic Medical CenterscoreStrategic or Co-development PartnerGeninus maintains ongoing partnerships with leading global academic medical centers to continuously expand their proprietary multimodal patient dataset. These collaborations provide access to patient tissue samples and clinical data that feed into the IntelliMed™ platform, enabling the company to grow their 5,500+ sample database and treatment response-linked spatial datasets. The relationship is described as mutually beneficial - academic partners contribute data while Geninus provides analytical capabilities and insights.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• 10x Genomics: Provider of spatial transcriptomics platforms (including Xenium) that Geninus uses and competes alongside for spatial-biology-driven oncology discovery workflows. Directly comparable technology layer for pharma customers.
• Bruker Spatial Biology (formerly NanoString): Offers GeoMx and CosMx spatial omics platforms used in oncology target discovery and tumor microenvironment profiling. Competes with Geninus for spatial-data-driven pharma engagements.
• Akoya Biosciences: Spatial biology company offering multiplexed protein profiling platforms (CODEX/Phenoptics) used in tumor microenvironment characterization. Competes with IntelliMed's multiplexed spatial protein layer.

Emerging players

• Owkin: AI-based precision medicine company applying multimodal patient data (including spatial) to oncology target discovery. Direct competitor for pharma AI-target-discovery deals.
• PathAI: AI-driven pathology platform combining H&E and molecular data for biomarker and target discovery. Comparable on the H&E + multi-modal data integration axis.
• Immunai: Single-cell and spatial immunology platform generating proprietary datasets for immune-mediated target discovery. Comparable modality (single-cell + spatial) and pharma GTM.

Regional players

• Standard BioTools (formerly Fluidigm): Provides spatial biology and multi-omics instrumentation used in translational research. Less direct overlap with Geninus's AI-target-discovery layer but comparable in spatial-omics tools category.

Broad incumbents

• Tempus AI: Large multimodal clinical and molecular data platform serving pharma for target discovery, biomarker development, and clinical-trial support. Competes for pharma data-licensing and target-discovery budgets.
• Insitro: Machine-learning-driven drug discovery company building proprietary multimodal datasets for target identification. Comparable business model of monetizing proprietary data assets to pharma.
• Recursion Pharmaceuticals: AI-enabled drug discovery platform combining proprietary biological data with ML. Broader in scope than Geninus but competes for pharma AI-discovery budgets in oncology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/geninus_inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geninus